ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000052 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 5, 2026 |
| Document | View SEC Filing |
Transactions
16
Total Shares
18,741
Total Value
$1,130,131.45
P&L
+inf% (+$4,760,280.33)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Grant/Award | 4,769 | $0.00 | $0.00 | 26,898 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 50 | $323.62 | $16,181.00 | 26,848 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 97 | $324.65 | $31,491.05 | 26,751 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 277 | $325.63 | $90,199.51 | 26,474 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 421 | $326.81 | $137,587.01 | 26,053 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 353 | $327.67 | $115,667.51 | 25,700 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 107 | $328.71 | $35,171.97 | 25,593 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 182 | $329.71 | $60,007.22 | 25,411 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 87 | $330.85 | $28,783.95 | 25,324 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 101 | $331.93 | $33,524.93 | 25,223 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 2, 2026 | Sale | 42 | $332.64 | $13,970.88 | 25,181 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 3, 2026 | Sale | 355 | $316.74 | $112,442.70 | 24,826 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 3, 2026 | Sale | 317 | $319.06 | $101,142.02 | 24,509 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 3, 2026 | Sale | 640 | $320.48 | $205,107.20 | 23,869 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Mar 3, 2026 | Sale | 463 | $321.50 | $148,854.50 | 23,406 | Direct | โ | View Details | |
EVP Chief R&D | Stock Option (right to buy) | Derivative | Mar 2, 2026 | Grant/Award | 10,480 | $0.00 | $0.00 | 10,480 | Direct | โ | View Details |